Mode
Text Size
Log in / Sign up

Case report and literature review on IgG4-related disease misdiagnosed as pancreatic cancer in a 70-year-old maleA 70-year-old man avoided unnecessary surgery after doctors found a treatable autoimmune condition

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider incorporating IgG4-related disease into the differential diagnosis to avoid overtreatment of pancreatic masses.

This publication is a case report and literature review focusing on the diagnostic challenge of distinguishing IgG4-related autoimmune pancreatitis from pancreatic ductal adenocarcinoma. The scope includes a detailed analysis of a 70-year-old male patient who presented with a lesion initially suspected to be pancreatic cancer. Postoperative pathological and immunohistochemical examinations confirmed the lesion was autoimmune pancreatitis secondary to IgG4-related sclerosing disease, with no malignant components identified. The review synthesizes the importance of recognizing these inflammatory characteristics to prevent unnecessary surgical interventions.

The authors argue that incorporating IgG4-related disease into the routine differential diagnosis can serve as a beneficial relative reference clue. Early recognition of the disease's inflammatory characteristics combined with multidisciplinary assessment can facilitate the transition of treatment strategies from surgical resection to pharmacological management. This approach aims to optimize clinical decision-making and avoid overtreatment in patients with IgG4-related sclerosing disease. The review highlights how multidisciplinary assessment is critical for accurate diagnosis and appropriate management strategies.

The study is limited by its reliance on a single patient case and a literature review, with no reported sample size beyond one individual. Follow-up duration and specific adverse events were not reported. Because the evidence is derived from a single case, the findings cannot be generalized to all patients with pancreatic masses. Clinicians should interpret these results with caution and consider the specific context of each patient before altering standard diagnostic or treatment protocols.

A 70-year-old man walked into a hospital with a mass in his pancreas. Doctors suspected cancer, a serious and often deadly form of pancreatic ductal adenocarcinoma. This type of tumor is hard to treat and usually requires major surgery. The patient faced a difficult choice: proceed with a risky operation or wait for more tests. His medical team chose to look closer at the details of his case. They examined the tissue from his pancreas using special staining techniques called pathological and immunohistochemical examinations. These tests looked for specific markers that tell the difference between cancer and other conditions. The results were surprising. The lesion was not cancer. Instead, it was autoimmune pancreatitis secondary to IgG4-related sclerosing disease. This is a rare inflammatory condition that mimics cancer but responds well to medication. Because the team recognized this specific disease early, they avoided a major surgical resection. This case highlights how important it is to consider autoimmune diseases like IgG4-related disease when looking at pancreatic masses. Early recognition of these inflammatory characteristics allows doctors to shift treatment strategies from surgery to drugs. This change in approach optimizes clinical decision-making and helps avoid overtreatment. While this is a single patient story, it shows how careful diagnosis can save patients from unnecessary harm. It serves as a beneficial reference clue for doctors facing similar cases.

What this means for you:
Recognizing autoimmune pancreatitis early can prevent unnecessary surgery and lead to better treatment with medication.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedMay 2026
View Original Abstract ↓
BackgroundWhen IgG4-related sclerosing disease (IgG4-RD) involves the pancreas, it frequently manifests as focal mass formation. These lesions clinically and radiographically closely mimic pancreatic ductal adenocarcinoma, often leading to unnecessary invasive interventions. Clarifying the diagnostic difficulties in differentiating focal mass-forming IgG4-RD from malignancies is of great significance for optimizing initial clinical assessment and management workflows.MethodsThis study reports the complete clinical course of a 70-year-old male patient who presented with a complaint of upper abdominal bloating, manifesting as a pancreatic head mass accompanied by a significant elevation of the tumor marker CA19-9 and biliary obstruction. Due to a high preoperative suspicion of malignancy and diagnostic challenges, the patient underwent a pancreaticoduodenectomy. Concurrently, this study conducted a systematic review and analysis of previous literature related to IgG4-RD presenting as focal pancreatic space-occupying lesions to explore the common diagnostic pathways and potential pitfalls in such cases.ResultsThe patient’s postoperative pathological and immunohistochemical examinations ultimately confirmed that the lesion was autoimmune pancreatitis secondary to IgG4-related sclerosing disease, with no malignant components identified. The literature review further indicated that, in the early stages of the disease when clear evidence of systemic involvement is lacking, the space-occupying effect on imaging often dominates the diagnostic pathway, obscuring its immune-mediated inflammatory nature.ConclusionFor patients with suspected pancreatic tumors, incorporating IgG4-RD into the routine differential diagnosis can serve as a beneficial relative reference clue. Provided that malignancy is strictly evaluated and excluded through methods such as endoscopic ultrasound-guided tissue biopsy, early recognition of the disease’s inflammatory characteristics combined with multidisciplinary assessment can facilitate the transition of treatment strategies from surgical resection to pharmacological management, thereby optimizing clinical decision-making and avoiding overtreatment.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.